Note: Unnecessary use of -X or --request, POST is already inferred.
  % Total    % Received % Xferd  Average Speed   Time    Time     Time  Current
                                 Dload  Upload   Total   Spent    Left  Speed
  0     0    0     0    0     0      0      0 --:--:-- --:--:-- --:--:--     0*   Trying 127.0.0.1:8000...
* Connected to 127.0.0.1 (127.0.0.1) port 8000
> POST /api/ayesha/complete_care_v2 HTTP/1.1
> Host: 127.0.0.1:8000
> User-Agent: curl/8.6.0
> Accept: */*
> Content-Type: application/json
> Authorization: Bearer mock-token
> Content-Length: 460
> 
} [460 bytes data]
< HTTP/1.1 200 OK
< date: Fri, 30 Jan 2026 19:15:29 GMT
< server: uvicorn
< content-length: 75408
< content-type: application/json
< x-content-type-options: nosniff
< x-frame-options: DENY
< referrer-policy: strict-origin-when-cross-origin
< content-security-policy: default-src 'self'; script-src 'self' 'unsafe-inline' 'unsafe-eval'; style-src 'self' 'unsafe-inline'; img-src 'self' data: https:; font-src 'self' data:; connect-src 'self' https:; frame-ancestors 'none';
< permissions-policy: geolocation=(), microphone=(), camera=(), payment=(), usb=()
< x-xss-protection: 1; mode=block
< 
{ [16332 bytes data]
{"trials":{"trials":[{"nct_id":"NCT02101775","title":"Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","phases":null,"phase":null,"conditions":"[\"gynecologic_oncology\"]","interventions":["Adavosertib","Gemcitabine Hydrochloride","Laboratory Biomarker Analysis","Pharmacological Study","Placebo Administration","Questionnaire Administration"],"score":0.0,"match_score":0.0,"keyword_matches":{},"combo_matches":[],"is_tagged":false,"reasoning":{"why_eligible":["Matches Ovarian Cancer query","Status: ACTIVE_NOT_RECRUITING"],"why_good_fit":["Runtime MoA Confidence: 0.8"],"whats_required":["Review protocol"]},"locations":[{"facility":"City of Hope Comprehensive Cancer Center","city":"Duarte","state":"California","zip":"91010","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"City of Hope South Pasadena","city":"South Pasadena","state":"California","zip":"91030","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"University of Chicago Comprehensive Cancer Center","city":"Chicago","state":"Illinois","zip":"60637","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Decatur Memorial Hospital","city":"Decatur","state":"Illinois","zip":"62526","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Indiana University/Melvin and Bren Simon Cancer Center","city":"Indianapolis","state":"Indiana","zip":"46202","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Mayo Clinic in Rochester","city":"Rochester","state":"Minnesota","zip":"55905","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Fox Chase Cancer Center","city":"Philadelphia","state":"Pennsylvania","zip":"19111","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"University of Pittsburgh Cancer Institute (UPCI)","city":"Pittsburgh","state":"Pennsylvania","zip":"15232","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"BCCA-Cancer Centre for the Southern Interior","city":"Kelowna","state":"British Columbia","zip":"V1Y 5L3","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"BCCA-Vancouver Cancer Centre","city":"Vancouver","state":"British Columbia","zip":"V5Z 4E6","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"London Regional Cancer Program","city":"London","state":"Ontario","zip":"N6A 4L6","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Ottawa Hospital and Cancer Center-General Campus","city":"Ottawa","state":"Ontario","zip":"K1H 8L6","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"University Health Network Princess Margaret Cancer Center P2C","city":"Toronto","state":"Ontario","zip":"M5G 2M9","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"University Health Network-Princess Margaret Hospital","city":"Toronto","state":"Ontario","zip":"M5G 2M9","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"CHUM - Centre Hospitalier de l'Universite de Montreal","city":"Montreal","state":"Quebec","zip":"H2X 3E4","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""}],"source_url":"https://clinicaltrials.gov/study/NCT02101775","holistic_score":0.45,"mechanism_fit_score":0.5,"eligibility_score":0.0,"pgx_safety_score":1.0,"holistic_interpretation":"INELIGIBLE","holistic_recommendation":"❌ INELIGIBLE for NCT02101775: Patient does not meet hard eligibility criteria (recruiting status, age, or other requirements). Consider alternative trials.","holistic_caveats":["Mechanism vector not available - using default 0.5"]},{"nct_id":"NCT03458221","title":"Signal TrAnsduction Pathway Activity Analysis in OVarian cancER","status":"RECRUITING","phases":null,"phase":null,"conditions":"[\"gynecologic_oncology\"]","interventions":["Letrozole Oral Product","Bicalutamide Oral Product","Everolimus Oral Product","Itraconazole Oral Product"],"score":0.0,"match_score":0.0,"keyword_matches":{},"combo_matches":[],"is_tagged":false,"reasoning":{"why_eligible":["Matches Ovarian Cancer query","Status: RECRUITING"],"why_good_fit":["Runtime MoA Confidence: 0.8"],"whats_required":["Review protocol"]},"locations":[{"facility":"Radboudumc","city":"Nijmegen","state":"Gelderland","zip":"","country":"Netherlands","status":"NOT_YET_RECRUITING","contact_name":"L Massuger, Prof","contact_phone":"","contact_email":"l.massuger@obgyn.umcn.nl"},{"facility":"Catharina Ziekenhuis","city":"Eindhoven","state":"North Brabant","zip":"5623EJ","country":"Netherlands","status":"RECRUITING","contact_name":"Jurgen M Piek, MD. PhD.","contact_phone":"+31(0)40 239 9111","contact_email":"jurgen.piek@catharinaziekenhuis.nl"}],"source_url":"https://clinicaltrials.gov/study/NCT03458221","holistic_score":0.45,"mechanism_fit_score":0.5,"eligibility_score":0.0,"pgx_safety_score":1.0,"holistic_interpretation":"INELIGIBLE","holistic_recommendation":"❌ INELIGIBLE for NCT03458221: Patient does not meet hard eligibility criteria (recruiting status, age, or other requirements). Consider alternative trials.","holistic_caveats":["Mechanism vector not available - using default 0.5"]},{"nct_id":"NCT03842982","title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)","status":"RECRUITING","phases":null,"phase":null,"conditions":"[\"gynecologic_oncology\"]","interventions":["HIPEC"],"score":0.0,"match_score":0.0,"keyword_matches":{},"combo_matches":[],"is_tagged":false,"reasoning":{"why_eligible":["Matches Ovarian Cancer query","Status: RECRUITING"],"why_good_fit":["Runtime MoA Confidence: 0.8"],"whats_required":["Review protocol"]},"locations":[],"source_url":"https://clinicaltrials.gov/study/NCT03842982","holistic_score":0.45,"mechanism_fit_score":0.5,"eligibility_score":0.0,"pgx_safety_score":1.0,"holistic_interpretation":"INELIGIBLE","holistic_recommendation":"❌ INELIGIBLE for NCT03842982: Patient does not meet hard eligibility criteria (recruiting status, age, or other requirements). Consider alternative trials.","holistic_caveats":["Mechanism vector not available - using default 0.5"]},{"nct_id":"NCT04024878","title":"NeoVax With Nivolumab in Patients With Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","phases":null,"phase":null,"conditions":"[\"gynecologic_oncology\"]","interventions":["Nivolumab","NeoVax","Core Needle Biopsy"],"score":0.0,"match_score":0.0,"keyword_matches":{},"combo_matches":[],"is_tagged":false,"reasoning":{"why_eligible":["Matches Ovarian Cancer query","Status: ACTIVE_NOT_RECRUITING"],"why_good_fit":["Runtime MoA Confidence: 0.8"],"whats_required":["Review protocol"]},"locations":[{"facility":"Dana Farber Cancer Institute","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""}],"source_url":"https://clinicaltrials.gov/study/NCT04024878","holistic_score":0.45,"mechanism_fit_score":0.5,"eligibility_score":0.0,"pgx_safety_score":1.0,"holistic_interpretation":"INELIGIBLE","holistic_recommendation":"❌ INELIGIBLE for NCT04024878: Patient does not meet hard eligibility criteria (recruiting status, age, or other requirements). Consider alternative trials.","holistic_caveats":["Mechanism vector not available - using default 0.5"]},{"nct_id":"NCT04633239","title":"Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer","status":"RECRUITING","phases":null,"phase":null,"conditions":"[\"gynecologic_oncology\"]","interventions":["Abemaciclib","Biopsy Procedure","Biospecimen Collection","Olaparib"],"score":0.0,"match_score":0.0,"keyword_matches":{},"combo_matches":[],"is_tagged":false,"reasoning":{"why_eligible":["Matches Ovarian Cancer query","Status: RECRUITING"],"why_good_fit":["Runtime MoA Confidence: 0.8"],"whats_required":["Review protocol"]},"locations":[{"facility":"Mayo Clinic Hospital in Arizona","city":"Phoenix","state":"Arizona","zip":"85054","country":"United States","status":"ACTIVE_NOT_RECRUITING","contact_name":"","contact_phone":"","contact_email":""},{"facility":"UM Sylvester Comprehensive Cancer Center at Coral Gables","city":"Coral Gables","state":"Florida","zip":"33146","country":"United States","status":"ACTIVE_NOT_RECRUITING","contact_name":"","contact_phone":"","contact_email":""},{"facility":"UM Sylvester Comprehensive Cancer Center at Deerfield Beach","city":"Deerfield Beach","state":"Florida","zip":"33442","country":"United States","status":"ACTIVE_NOT_RECRUITING","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Mayo Clinic in Florida","city":"Jacksonville","state":"Florida","zip":"32224-9980","country":"United States","status":"RECRUITING","contact_name":"Site Public Contact","contact_phone":"855-776-0015","contact_email":""},{"facility":"University of Miami Miller School of Medicine-Sylvester Cancer Center","city":"Miami","state":"Florida","zip":"33136","country":"United States","status":"ACTIVE_NOT_RECRUITING","contact_name":"","contact_phone":"","contact_email":""},{"facility":"UM Sylvester Comprehensive Cancer Center at Plantation","city":"Plantation","state":"Florida","zip":"33324","country":"United States","status":"ACTIVE_NOT_RECRUITING","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Northwestern University","city":"Chicago","state":"Illinois","zip":"60611","country":"United States","status":"ACTIVE_NOT_RECRUITING","contact_name":"","contact_phone":"","contact_email":""},{"facility":"University of Kansas Clinical Research Center","city":"Fairway","state":"Kansas","zip":"66205","country":"United States","status":"RECRUITING","contact_name":"Site Public Contact","contact_phone":"913-588-3671","contact_email":"KUCC_Navigation@kumc.edu"},{"facility":"University of Kansas Cancer Center","city":"Kansas City","state":"Kansas","zip":"66160","country":"United States","status":"SUSPENDED","contact_name":"","contact_phone":"","contact_email":""},{"facility":"University of Kansas Cancer Center-Overland Park","city":"Overland Park","state":"Kansas","zip":"66210","country":"United States","status":"SUSPENDED","contact_name":"","contact_phone":"","contact_email":""},{"facility":"University of Kansas Hospital-Indian Creek Campus","city":"Overland Park","state":"Kansas","zip":"66211","country":"United States","status":"SUSPENDED","contact_name":"","contact_phone":"","contact_email":""},{"facility":"University of Kansas Hospital-Westwood Cancer Center","city":"Westwood","state":"Kansas","zip":"66205","country":"United States","status":"SUSPENDED","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Mayo Clinic in Rochester","city":"Rochester","state":"Minnesota","zip":"55905","country":"United States","status":"RECRUITING","contact_name":"Site Public Contact","contact_phone":"855-776-0015","contact_email":""},{"facility":"University of Kansas Cancer Center - North","city":"Kansas City","state":"Missouri","zip":"64154","country":"United States","status":"SUSPENDED","contact_name":"","contact_phone":"","contact_email":""},{"facility":"University of Kansas Cancer Center - Lee's Summit","city":"Lee's Summit","state":"Missouri","zip":"64064","country":"United States","status":"SUSPENDED","contact_name":"","contact_phone":"","contact_email":""},{"facility":"University of Kansas Cancer Center at North Kansas City Hospital","city":"North Kansas City","state":"Missouri","zip":"64116","country":"United States","status":"SUSPENDED","contact_name":"","contact_phone":"","contact_email":""},{"facility":"NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center","city":"New York","state":"New York","zip":"10032","country":"United States","status":"SUSPENDED","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Wake Forest University Health Sciences","city":"Winston-Salem","state":"North Carolina","zip":"27157","country":"United States","status":"RECRUITING","contact_name":"Site Public Contact","contact_phone":"336-713-6771","contact_email":""},{"facility":"Ohio State University Comprehensive Cancer Center","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","status":"RECRUITING","contact_name":"Site Public Contact","contact_phone":"800-293-5066","contact_email":"Jamesline@osumc.edu"},{"facility":"University of Oklahoma Health Sciences Center","city":"Oklahoma City","state":"Oklahoma","zip":"73104","country":"United States","status":"RECRUITING","contact_name":"Site Public Contact","contact_phone":"405-271-8777","contact_email":"ou-clinical-trials@ouhsc.edu"},{"facility":"Thomas Jefferson University Hospital","city":"Philadelphia","state":"Pennsylvania","zip":"19107","country":"United States","status":"RECRUITING","contact_name":"Site Public Contact","contact_phone":"215-600-9151","contact_email":"ONCTrialNow@jefferson.edu"},{"facility":"Vanderbilt University/Ingram Cancer Center","city":"Nashville","state":"Tennessee","zip":"37232","country":"United States","status":"RECRUITING","contact_name":"Site Public Contact","contact_phone":"800-811-8480","contact_email":""},{"facility":"University of Virginia Cancer Center","city":"Charlottesville","state":"Virginia","zip":"22908","country":"United States","status":"RECRUITING","contact_name":"Site Public Contact","contact_phone":"434-243-6303","contact_email":"uvacancertrials@hscmail.mcc.virginia.edu"}],"source_url":"https://clinicaltrials.gov/study/NCT04633239","holistic_score":0.45,"mechanism_fit_score":0.5,"eligibility_score":0.0,"pgx_safety_score":1.0,"holistic_interpretation":"INELIGIBLE","holistic_recommendation":"❌ INELIGIBLE for NCT04633239: Patient does not meet hard eligibility criteria (recruiting status, age, or other requirements). Consider alternative trials.","holistic_caveats":["Mechanism vector not available - using default 0.5"]},{"nct_id":"NCT04701645","title":"Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer","status":"RECRUITING","phases":null,"phase":null,"conditions":"[\"gynecologic_oncology\"]","interventions":["Microdevice"],"score":0.0,"match_score":0.0,"keyword_matches":{},"combo_matches":[],"is_tagged":false,"reasoning":{"why_eligible":["Matches Ovarian Cancer query","Status: RECRUITING"],"why_good_fit":["Runtime MoA Confidence: 0.8"],"whats_required":["Review protocol"]},"locations":[{"facility":"Brigham and Women's Hospital","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","status":"RECRUITING","contact_name":"Elizabeth Stover, MD, PhD","contact_phone":"(617) 632-5269","contact_email":"ehstover@partners.org"},{"facility":"Dana Farber Cancer Institute","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","status":"RECRUITING","contact_name":"Elizabeth Stover, MD, PhD","contact_phone":"(617) 632-5269","contact_email":"ehstover@partners.org"}],"source_url":"https://clinicaltrials.gov/study/NCT04701645","holistic_score":0.45,"mechanism_fit_score":0.5,"eligibility_score":0.0,"pgx_safety_score":1.0,"holistic_interpretation":"INELIGIBLE","holistic_recommendation":"❌ INELIGIBLE for NCT04701645: Patient does not meet hard eligibility criteria (recruiting status, age, or other requirements). Consider alternative trials.","holistic_caveats":["Mechanism vector not available - using default 0.5"]},{"nct_id":"NCT04938583","title":"Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer","status":"RECRUITING","phases":null,"phase":null,"conditions":"[\"gynecologic_oncology\"]","interventions":["Oregovomab","Bevacizumab","Paclitaxel","Carboplatin"],"score":0.0,"match_score":0.0,"keyword_matches":{},"combo_matches":[],"is_tagged":false,"reasoning":{"why_eligible":["Matches Ovarian Cancer query","Status: RECRUITING"],"why_good_fit":["Runtime MoA Confidence: 0.8"],"whats_required":["Review protocol"]},"locations":[],"source_url":"https://clinicaltrials.gov/study/NCT04938583","holistic_score":0.45,"mechanism_fit_score":0.5,"eligibility_score":0.0,"pgx_safety_score":1.0,"holistic_interpretation":"INELIGIBLE","holistic_recommendation":"❌ INELIGIBLE for NCT04938583: Patient does not meet hard eligibility criteria (recruiting status, age, or other requirements). Consider alternative trials.","holistic_caveats":["Mechanism vector not available - using default 0.5"]},{"nct_id":"NCT05116189","title":"Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)","status":"ACTIVE_NOT_RECRUITING","phases":null,"phase":null,"conditions":"[\"gynecologic_oncology\"]","interventions":["Pembrolizumab","Paclitaxel","Bevacizumab","Placebo for pembrolizumab","Docetaxel"],"score":0.0,"match_score":0.0,"keyword_matches":{},"combo_matches":[],"is_tagged":false,"reasoning":{"why_eligible":["Matches Ovarian Cancer query","Status: ACTIVE_NOT_RECRUITING"],"why_good_fit":["Runtime MoA Confidence: 0.8"],"whats_required":["Review protocol"]},"locations":[{"facility":"HonorHealth ( Site 0041)","city":"Phoenix","state":"Arizona","zip":"85016","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Marin Cancer Care ( Site 0055)","city":"Greenbrae","state":"California","zip":"94904","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Pacific Cancer Care ( Site 0028)","city":"Monterey","state":"California","zip":"93940","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Eisenhower Medical Center ( Site 0067)","city":"Rancho Mirage","state":"California","zip":"92270","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0004)","city":"New Haven","state":"Connecticut","zip":"06511","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"University of Florida College of Medicine-UF Health Cancer Center/Clinical Trials Office ( Site 0054","city":"Gainesville","state":"Florida","zip":"32610","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Sarasota Memorial Hospital ( Site 0018)","city":"Sarasota","state":"Florida","zip":"34239","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Moffitt Cancer Center ( Site 0033)","city":"Tampa","state":"Florida","zip":"33612","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0005)","city":"Marietta","state":"Georgia","zip":"30060","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Advocate Medical Group-Oncology ( Site 0049)","city":"Park Ridge","state":"Illinois","zip":"60068","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Parkview Research Center at Parkview Regional Medical Center ( Site 0027)","city":"Fort Wayne","state":"Indiana","zip":"46845","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"St. Vincent Hospital and Health Care Center, Inc ( Site 0032)","city":"Indianapolis","state":"Indiana","zip":"46260","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0040)","city":"Edgewood","state":"Kentucky","zip":"41017","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"WK Physicians Network / Hematology Oncology Associates ( Site 0034)","city":"Shreveport","state":"Louisiana","zip":"71103","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Mercy Medical Center - Baltimore-Medical Oncology and Hematology ( Site 0015)","city":"Baltimore","state":"Maryland","zip":"21202","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"University of Massachusetts Chan Medical School-Division of Gynecologic Oncology ( Site 0003)","city":"Worcester","state":"Massachusetts","zip":"01605","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"John Theurer Cancer Center at Hackensack University Medical Center ( Site 0007)","city":"Hackensack","state":"New Jersey","zip":"07601","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Roswell Park Cancer Institute ( Site 0039)","city":"Buffalo","state":"New York","zip":"14263","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Columbia University Medical Center ( Site 0010)","city":"New York","state":"New York","zip":"10032","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Novant Health Presbyterian Medical Center ( Site 0029)","city":"Charlotte","state":"North Carolina","zip":"28204","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Duke Cancer Institute ( Site 0038)","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Novant Health Forsyth Medical Center ( Site 0057)","city":"Winston-Salem","state":"North Carolina","zip":"27103","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Aultman Hospital-Oncology Clinical Trials ( Site 0009)","city":"Canton","state":"Ohio","zip":"44710","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"MetroHealth Medical Center-Cancer Care Center ( Site 0047)","city":"Cleveland","state":"Ohio","zip":"44109","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Providence Portland Medical Center ( Site 0048)","city":"Portland","state":"Oregon","zip":"97213","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0024)","city":"Pittsburgh","state":"Pennsylvania","zip":"15219","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Sanford Cancer Center ( Site 0064)","city":"Sioux Falls","state":"South Dakota","zip":"57104","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"The West Clinic, PLLC dba West Cancer Center ( Site 0058)","city":"Germantown","state":"Tennessee","zip":"38138","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Texas Oncology - Dallas (Presbyterian) ( Site 0065)","city":"Dallas","state":"Texas","zip":"75231","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Texas Oncology - The Woodlands_Lee ( Site 0043)","city":"The Woodlands","state":"Texas","zip":"77380","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Inova Schar Cancer Institute ( Site 0019)","city":"Fairfax","state":"Virginia","zip":"22031","country":"United States","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Westmead Hospital-Department of Gynaecological Oncology ( Site 0201)","city":"Westmead","state":"New South Wales","zip":"2145","country":"Australia","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Gallipoli Medical Research Foundation-GMRF CTU ( Site 0202)","city":"Brisbane","state":"Queensland","zip":"4120","country":"Australia","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Epworth Freemasons ( Site 0204)","city":"Melbourne","state":"Victoria","zip":"3002","country":"Australia","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"St. John of God Subiaco Hospital ( Site 0203)","city":"Subiaco","state":"Western Australia","zip":"6008","country":"Australia","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Institut Jules Bordet-Medicine Oncology ( Site 0302)","city":"Brussels","state":"Bruxelles-Capitale, Region de","zip":"1000","country":"Belgium","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"UZ Gent-Medical oncology ( Site 0301)","city":"Ghent","state":"Oost-Vlaanderen","zip":"9000","country":"Belgium","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"UZ Leuven ( Site 0303)","city":"Leuven","state":"Vlaams-Brabant","zip":"3000","country":"Belgium","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"AZ Groeninge Campus Kennedylaan-Oncology ( Site 0305)","city":"Kortrijk","state":"West-Vlaanderen","zip":"8500","country":"Belgium","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Hospital Araújo Jorge ( Site 0401)","city":"Goiânia","state":"Goiás","zip":"74605-070","country":"Brazil","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0404)","city":"Natal","state":"Rio Grande do Norte","zip":"59075-740","country":"Brazil","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"ANIMI - Unidade de Tratamento Oncologico ( Site 0408)","city":"Lages","state":"Santa Catarina","zip":"88501001","country":"Brazil","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"BP - A Beneficencia Portuguesa de São Paulo ( Site 0403)","city":"São Paulo","state":"São Paulo","zip":"01323-001","country":"Brazil","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0405)","city":"São Paulo","state":"São Paulo","zip":"04014-002","country":"Brazil","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Tom Baker Cancer Center ( Site 0511)","city":"Calgary","state":"Alberta","zip":"T2N 4N2","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"BC Cancer Abbotsford ( Site 0512)","city":"Abbotsford","state":"British Columbia","zip":"V2S 0C2","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"BC Cancer Victoria ( Site 0513)","city":"Victoria","state":"British Columbia","zip":"V8R 6V5","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Kingston Health Sciences Centre-Kingston General Hospital Si-Oncology and/or Hematology - Gynecolog","city":"Kingston","state":"Ontario","zip":"K7L 2V7","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0508)","city":"Toronto","state":"Ontario","zip":"M4N 3M5","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"CIUSSS de l'Est-de-l'Île-de-Montréal ( Site 0501)","city":"Montreal","state":"Quebec","zip":"H1T 2M4","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Jewish General Hospital ( Site 0505)","city":"Montreal","state":"Quebec","zip":"H3T 1E2","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"McGill University Health Centre ( Site 0502)","city":"Montreal","state":"Quebec","zip":"H4A 3J1","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0","city":"Québec","state":"Quebec","zip":"G1J 1Z4","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Saskatoon Cancer Center ( Site 0510)","city":"Saskatoon","state":"Saskatchewan","zip":"S7N 4H4","country":"Canada","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Clínica Puerto Montt ( Site 0601)","city":"Port Montt","state":"Los Lagos Region","zip":"5500243","country":"Chile","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Oncovida ( Site 0603)","city":"Santiago","state":"Region M. de Santiago","zip":"7510032","country":"Chile","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Instituto de Radiomedicina-hemato-oncologia ( Site 0604)","city":"Santiago","state":"Region M. de Santiago","zip":"7630370","country":"Chile","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Clínica Vespucio-Hemato - Ocology ( Site 0607)","city":"Santiago","state":"Region M. de Santiago","zip":"8241479","country":"Chile","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Pontificia Universidad Catolica de Chile-Centro del Cáncer ( Site 0609)","city":"Santiago","state":"Region M. de Santiago","zip":"8330032","country":"Chile","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Bradfordhill ( Site 0605)","city":"Santiago","state":"Region M. de Santiago","zip":"8420383","country":"Chile","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"James Lind Centro de Investigación del Cáncer ( Site 0602)","city":"Temuco","state":"Región de la Araucanía","zip":"4780000","country":"Chile","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"CIDO SpA-Oncology ( Site 0608)","city":"Temuco","state":"Región de la Araucanía","zip":"4810148","country":"Chile","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Anhui Provincial Hospital-Obstetrics and Gynecology ( Site 0709)","city":"Hefei","state":"Anhui","zip":"230001","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Beijing Cancer hospital ( Site 0711)","city":"Beijing","state":"Beijing Municipality","zip":"100142","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Beijing Peking Union Medical College Hospital-Gynecological center of tumor ( Site 0702)","city":"Beijing","state":"Beijing Municipality","zip":"100730","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Fujian Provincial Cancer Hospital ( Site 0713)","city":"Fuzhou","state":"Fujian","zip":"350014","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Lanzhou university second hospital ( Site 0734)","city":"Lanzhou","state":"Gansu","zip":"730030","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Zhujiang Hospital ( Site 0739)","city":"Guangzhou","state":"Guangdong","zip":"510280","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Affiliated Hospital of Guangdong Medical University ( Site 0743)","city":"Zhanjiang","state":"Guangdong","zip":"524004","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Guangxi Medical University Affiliated Tumor Hospital ( Site 0717)","city":"Nanning","state":"Guangxi","zip":"530021","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Hainan General Hospital ( Site 0736)","city":"Haikou","state":"Hainan","zip":"570311","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Henan Cancer Hospital ( Site 0718)","city":"Zhengzhou","state":"Henan","zip":"450008","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Wuhan Union Hospital-Medical Oncology ( Site 0735)","city":"Wuhan","state":"Hubei","zip":"430022","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Hubei Cancer Hospital-Hubei Cancer Hospital ( Site 0708)","city":"Wuhan","state":"Hubei","zip":"430079","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Xiangya Hospital Central South University-Gynecology ( Site 0705)","city":"Changsha","state":"Hunan","zip":"410008","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Hunan Cancer Hospital ( Site 0704)","city":"Changsha","state":"Hunan","zip":"410013","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology (","city":"Nanjing","state":"Jiangsu","zip":"210000","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Zhongda Hospital Southeast University ( Site 0723)","city":"Nanjing","state":"Jiangsu","zip":"","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Jiangxi Maternal and Child Health Hospital-Oncology Department ( Site 0716)","city":"Nanchang","state":"Jiangxi","zip":"330006","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"The First Hospital of Jilin University ( Site 0710)","city":"Changchun","state":"Jilin","zip":"130021","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Shandong Cancer Hospital-Oncology Department ( Site 0733)","city":"Jinan","state":"Shandong","zip":"250117","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"LinYi Cancer Hospital ( Site 0731)","city":"Linyi","state":"Shandong","zip":"276001","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Obstetrics & Gynecology Hospital of Fudan University ( Site 0715)","city":"Shanghai","state":"Shanghai Municipality","zip":"200011","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Fudan University Shanghai Cancer Center-Gynecologic Oncology Department ( Site 0701)","city":"Shanghai","state":"Shanghai Municipality","zip":"200032","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 0744)","city":"Shanghai","state":"Shanghai Municipality","zip":"201204","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"West China Second University Hospital Sichuan University ( Site 0740)","city":"Chengdu","state":"Sichuan","zip":"610066","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Tianjin Central Hosptial of Gynecology Obstetrics ( Site 0737)","city":"Tianjin","state":"Tianjin Municipality","zip":"300052","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Tianjin Medical University Cancer Institute and Hospital ( Site 0720)","city":"Tianjin","state":"Tianjin Municipality","zip":"300060","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Yunnan Province Cancer Hospital-Gynecology Department ( Site 0714)","city":"Kunming","state":"Yunnan","zip":"650106","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"The Affiliated Women's Hospital of Zhejiang University-Obstetrics and Gynecology ( Site 0741)","city":"Hangzhou","state":"Zhejiang","zip":"3100000","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"The First Affiliated Hospital of Wenzhou Medical University-Gynecology ( Site 0706)","city":"Wenzhou","state":"Zhejiang","zip":"325000","country":"China","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Fundación Colombiana de Cancerología Clínica Vida ( Site 0808)","city":"Medellín","state":"Antioquia","zip":"050030","country":"Colombia","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Clinica de la Costa LTDA-Clinical Research Oncology & Hematology -Pediatric ( Site 0809)","city":"Barranquilla","state":"Atlántico","zip":"080020","country":"Colombia","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Clínica Universitaria Colombia ( Site 0806)","city":"Bogotá","state":"Bogota D.C.","zip":"111221","country":"Colombia","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Oncologos del Occidente ( Site 0807)","city":"Pereira","state":"Risaralda Department","zip":"660001","country":"Colombia","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Hemato Oncologos SA ( Site 0801)","city":"Cali","state":"Valle del Cauca Department","zip":"76001","country":"Colombia","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Aalborg Universitetshospital, Syd ( Site 0901)","city":"Aalborg","state":"North Denmark","zip":"9000","country":"Denmark","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Turku University Hospital-Department of Obstetrics and Gynecology ( Site 1001)","city":"Turku","state":"Southwest Finland","zip":"20521","country":"Finland","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Centre Hospitalier Régional Universitaire de Brest - Hôpital-Institut de cancérologie et hématologi","city":"Brest","state":"Brittany Region","zip":"29200","country":"France","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Centre François Baclesse-Recherche clinique ( Site 2904)","city":"Caen","state":"Calvados","zip":"14076","country":"France","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren-oncologie ( Site 2907)","city":"Limoges","state":"Haute-Vienne","zip":"87042","country":"France","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Institut Curie - site Saint-Cloud ( Site 2909)","city":"Saint-Cloud","state":"Hauts-de-Seine","zip":"92210","country":"France","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 2901)","city":"Rennes","state":"Ille-et-Vilaine","zip":"35042","country":"France","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Centre de Cancérologie du Grand Montpellier ( Site 2908)","city":"Montpellier","state":"Languedoc-Roussillon","zip":"34070","country":"France","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Hôpital privé du Confluent SAS-Service d'oncologie médicale ( Site 2905)","city":"Nantes","state":"Loire-Atlantique","zip":"44277","country":"France","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Universitaetsklinikum Erlangen-Klinik für Gynäkologie und Geburtshilfe ( Site 1205)","city":"Erlangen","state":"Bavaria","zip":"91054","country":"Germany","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Universitätsklinikum Bonn-Gynaecological oncology ( Site 1203)","city":"Bonn","state":"North Rhine-Westphalia","zip":"53127","country":"Germany","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Universitaetsklinikum Duesseldorf-Klinik für Frauenheilkunde & Geburtshilfe ( Site 1204)","city":"Düsseldorf","state":"North Rhine-Westphalia","zip":"40225","country":"Germany","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Zentrum fuer ambulante gynaekologische Onkologie (ZAGO) ( Site 1207)","city":"Krefeld","state":"North Rhine-Westphalia","zip":"47805","country":"Germany","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"CaritasKlinikum Saarbrücken St. Theresia ( Site 1211)","city":"Saarbrücken","state":"Saarland","zip":"66113","country":"Germany","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Frauenheilkunde und Gebur","city":"Dresden","state":"Saxony","zip":"01307","country":"Germany","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Universitätsklinikum Leipzig-Department of Gynecology and Obstetrics ( Site 1213)","city":"Leipzig","state":"Saxony","zip":"04103","country":"Germany","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"IRCCS - AOU di Bologna-SSD Oncologia medica Addarii ( Site 1501)","city":"Bologna","state":"Emilia-Romagna","zip":"40138","country":"Italy","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1503)","city":"Milan","state":"Lombardy","zip":"20133","country":"Italy","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Ospedale San Gerardo-ASST Monza-Oncologia ( Site 1508)","city":"Monza","state":"Lombardy","zip":"20900","country":"Italy","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"ASST Grande Ospedale Metropolitano Niguarda ( Site 1505)","city":"Milan","state":"Milano","zip":"20162","country":"Italy","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Ospedale Mauriziano-Ginecologia e Ostetricia ( Site 1507)","city":"Turin","state":"Piedmont","zip":"10128","country":"Italy","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Aichi Cancer Center Hospital ( Site 1610)","city":"Nagoya","state":"Aichi-ken","zip":"464-8681","country":"Japan","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"National Cancer Center Hospital East ( Site 1609)","city":"Kashiwa","state":"Chiba","zip":"277-8577","country":"Japan","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"National Hospital Organization Shikoku Cancer Center ( Site 1603)","city":"Matsuyama","state":"Ehime","zip":"791-0280","country":"Japan","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Ehime University Hospital ( Site 1606)","city":"Tōon","state":"Ehime","zip":"791-0295","country":"Japan","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Kurume University Hospital ( Site 1607)","city":"Kurume","state":"Fukuoka","zip":"830-0011","country":"Japan","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Hokkaido University Hospital ( Site 1604)","city":"Sapporo","state":"Hokkaido","zip":"060-8648","country":"Japan","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Iwate Medical University Hospital ( Site 1613)","city":"Shiwa-gun Yahaba-cho","state":"Iwate","zip":"028-3695","country":"Japan","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Nippon Medical School Musashi Kosugi Hospital ( Site 1614)","city":"Kawasaki","state":"Kanagawa","zip":"211-8533","country":"Japan","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Saitama Medical University International Medical Center ( Site 1601)","city":"Hidaka-shi","state":"Saitama","zip":"350-1200","country":"Japan","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Shizuoka Cancer Center ( Site 1611)","city":"Nakatogari","state":"Shizuoka","zip":"411-8777","country":"Japan","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"National Cancer Center Hospital ( Site 1612)","city":"Chuo-ku","state":"Tokyo","zip":"104-0045","country":"Japan","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Japanese Foundation for Cancer Research ( Site 1605)","city":"Koto","state":"Tokyo","zip":"135-8550","country":"Japan","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Investigación Oncofarmacéutica-Investigación clínica ( Site 1706)","city":"La Paz","state":"Baja California Sur","zip":"23040","country":"Mexico","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"COI Centro Oncologico Internacional S.A.P.I. de C.V.-Investigation Unit COI ( Site 1703)","city":"Mexico City","state":"Mexico City","zip":"04700","country":"Mexico","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"INSTITUTO NACIONAL DE CANCEROLOGIA ( Site 1701)","city":"Mexico City","state":"Mexico City","zip":"14070","country":"Mexico","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"iCan Oncology Center Centro Medico AVE ( Site 1704)","city":"Monterrey","state":"Nuevo León","zip":"64710","country":"Mexico","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Radboudumc ( Site 1802)","city":"Nijmegen","state":"Gelderland","zip":"6525 GA","country":"Netherlands","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Leids Universitair Medisch Centrum-Medical Oncology ( Site 1801)","city":"Leiden","state":"South Holland","zip":"2333 ZA","country":"Netherlands","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Erasmus Medisch Centrum-Medical Oncology ( Site 1803)","city":"Rotterdam","state":"South Holland","zip":"3015 GD","country":"Netherlands","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Universitetssykehuset Nord-Norge HF-Kreftavdelingen ( Site 2001)","city":"Tromsø","state":"Troms","zip":"9038","country":"Norway","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Me-Oddzial Ginekologii Onkologicznej ( Sit","city":"Poznan","state":"Greater Poland Voivodeship","zip":"61-848","country":"Poland","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Szpital Kliniczny im. Księżnej Anny Mazowieckiej ( Site 2103)","city":"Warsaw","state":"Masovian Voivodeship","zip":"00-315","country":"Poland","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Gynecological Oncology Department ( Sit","city":"Warsaw","state":"Masovian Voivodeship","zip":"02-781","country":"Poland","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Bialostockie Centrum Onkologii-Oddzial Onkologii Ginekologicznej ( Site 2106)","city":"Bialystok","state":"Podlaskie Voivodeship","zip":"15-027","country":"Poland","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Uniwersytecki Szpital Kliniczny w Bialymstoku-Uniwersyteckie Centrum Onkologii ( Site 2104)","city":"Bialystok","state":"Podlaskie Voivodeship","zip":"15-276","country":"Poland","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Uniwersyteckie Centrum Kliniczne-Klinika Ginekologii, Ginekologii Onkologicznej i Endokrynologii Gi","city":"Gdansk","state":"Pomeranian Voivodeship","zip":"80-214","country":"Poland","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Narodowy Instytut Onkologii - Oddzial w Gliwicach-III Klinika Radioterapii i Chemioterapii ( Site 21","city":"Gliwice","state":"Silesian Voivodeship","zip":"44-101","country":"Poland","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 2107)","city":"Kielce","state":"Świętokrzyskie Voivodeship","zip":"25-734","country":"Poland","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Chelyabinsk Regional Clinical Oncology Dispensary-Chelyabinsk Regional Clinical Oncology Dispensary","city":"Chelyabinsk","state":"Chelyabinsk Oblast","zip":"454087","country":"Russia","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Ogarev Mordovia State University ( Site 2209)","city":"Saransk","state":"Mordoviya, Respublika","zip":"430005","country":"Russia","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Fed State Budgetary Inst \"N.N. Blokhin Med Center of Oncology\" MHRF-Chemotherapy #2 ( Site 2211)","city":"Moscow","state":"Moscow","zip":"115478","country":"Russia","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Moscow City Oncology Hospital #62 ( Site 2214)","city":"Krasnogorsk D-t","state":"Moscow Oblast","zip":"143423","country":"Russia","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"SVERDLOVSK REGIONAL ONCOLOGY DISPENSARY-Oncogynecology Department ( Site 2216)","city":"Yekaterinburg","state":"Sverdlovsk Oblast","zip":"620905","country":"Russia","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"cukurova universty ( Site 2706)","city":"Sarçam","state":"Adana","zip":"01250","country":"Turkey (Türkiye)","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Istanbul Universitesi Cerrahpasa ( Site 2709)","city":"Fatih","state":"Istanbul","zip":"34098","country":"Turkey (Türkiye)","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Ege University Medicine of Faculty ( Site 2702)","city":"Bornova","state":"İzmir","zip":"35100","country":"Turkey (Türkiye)","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Brighton and Sussex University Hospitals NHS Trust ( Site 2803)","city":"East Sussex","state":"Brighton And Hove","zip":"BN2 5BE","country":"United Kingdom","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Addenbrooke's Hospital ( Site 2808)","city":"Cambridge","state":"Cambridgeshire","zip":"CB2 2QQ","country":"United Kingdom","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"The Royal Cornwall Hospital ( Site 2804)","city":"Truro","state":"Cornwall","zip":"TR1 3LJ","country":"United Kingdom","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Westmorland General Hospital ( Site 2815)","city":"Kendal","state":"Cumbria","zip":"LA9 7RG","country":"United Kingdom","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Ninewells Hospital and Medical School ( Site 2826)","city":"Dundee","state":"Dundee City","zip":"DD1 9SY","country":"United Kingdom","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Leicester Royal Infirmary-HOPE Clinical Trials Unit ( Site 2812)","city":"Leicester","state":"England","zip":"","country":"United Kingdom","status":"","contact_name":"","contact_phone":"","contact_email":""},{"facility":"Hammersmith Hospital-Medical Oncology ( Site 2818)","city":"London","state":"London, City of","zip":"W12 0HS","country":"United Kingdom","status":"","contact_name":"","contact_phone":"","contact_email":""}],"source_url":"https://clinicaltrials.gov/study/NCT05116189","holistic_score":0.45,"mechanism_fit_score":0.5,"eligibility_score":0.0,"pgx_safety_score":1.0,"holistic_interpretation":"INELIGIBLE","holistic_recommendation":"❌ INELIGIBLE for NCT05116189: Patient does not meet hard eligibility criteria (recruiting status, age, or other requirements). Consider alternative trials.","holistic_caveats":["Mechanism vector not available - using default 0.5"]},{"nct_id":"NCT05123807","title":"Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)","status":"RECRUITING","phases":null,"phase":null,"conditions":"[\"gynecologic_oncology\"]","interventions":["Cytoreductive surgery"],"score":0.0,"match_score":0.0,"keyword_matches":{},"combo_matches":[],"is_tagged":false,"reasoning":{"why_eligible":["Matches Ovarian Cancer query","Status: RECRUITING"],"why_good_fit":["Runtime MoA Confidence: 0.8"],"whats_required":["Review protocol"]},"locations":[{"facility":"MD Anderson Cancer Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","status":"RECRUITING","contact_name":"Aaron Shafer","contact_phone":"832-885-6133","contact_email":"AShafer@mdanderson.org"}],"source_url":"https://clinicaltrials.gov/study/NCT05123807","holistic_score":0.45,"mechanism_fit_score":0.5,"eligibility_score":0.0,"pgx_safety_score":1.0,"holistic_interpretation":"INELIGIBLE","holistic_recommendation":"❌ INELIGIBLE for NCT05123807: Patient does not meet hard eligibility criteria (recruiting status, age, or other requirements). Consider alternative trials.","holistic_caveats":["Mechanism vector not available - using default 0.5"]},{"nct_id":"NCT05233982","title":"MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer","status":"RECRUITING","phases":null,"phase":null,"conditions":"[\"gynecologic_oncology\"]","interventions":["Olaparib Oral Product"],"score":0.0,"match_score":0.0,"keyword_matches":{},"combo_matches":[],"is_tagged":false,"reasoning":{"why_eligible":["Matches Ovarian Cancer query","Status: RECRUITING"],"why_good_fit":["Runtime MoA Confidence: 0.8"],"whats_required":["Review protocol"]},"locations":[],"source_url":"https://clinicaltrials.gov/study/NCT05233982","holistic_score":0.45,"mechanism_fit_score":0.5,"eligibility_score":0.0,"pgx_safety_score":1.0,"holistic_interpretation":"INELIGIBLE","holistic_recommendation":"❌ INELIGIBLE for NCT05233982: Patient does not meet hard eligibility criteria (recruiting status, age, or other requirements). Consider alternative trials.","holistic_caveats":["Mechanism vector not available - using default 0.5"]}],"summary":{"total_found":10,"note":"Intent-gated ranking: 10 therapeutic drug trials aligned to Ayesha's profile (MBD4/BER, TP53, PD-L1+). Non-therapeutic studies excluded.","ranking_method":"intent_gated_ayesha_v1"},"provenance":{}},"soc_recommendation":{"regimen":"Carboplatin AUC 5-6 + Paclitaxel 175 mg/m²","confidence":0.95,"rationale":"NCCN Category 1 for first-line Stage IVB HGSOC","engine_validation":null,"add_ons":[],"evidence":["NCCN Guidelines v2024","GOG-218","ICON7"]},"ca125_intelligence":{"burden_class":"EXTENSIVE","burden_score":0.7775280682546419,"forecast":{"complete_response_target":35,"complete_response_target_unit":"U/mL","note":"Baseline CA-125 not available. General expectations: ≥70% drop by cycle 3, ≥90% by cycle 6 for chemo-sensitive disease."},"resistance_signals":[],"monitoring_strategy":{"frequency":"every_2_weeks","timing":"Until treatment initiation","rationale":"High baseline; track any changes before treatment","method":"Serum CA-125 (U/mL)"},"clinical_notes":"CA-125 of 2842.0 U/mL indicates EXTENSIVE disease burden (>1,000). CA-125 is highly trackable and suitable for response monitoring. Complete response target: <35 U/mL. Additional therapy cycles likely needed.","provenance":{"method":"ca125_intelligence_v1","data_sources":["GOG-218","ICON7","NCCN Guidelines v2024"],"thresholds":{"MINIMAL":[0,100],"MODERATE":[100,500],"SIGNIFICANT":[500,1000],"EXTENSIVE":[1000,null]},"expectations":{"cycle3_drop_percent":70,"cycle6_drop_percent":90,"complete_response_threshold":35,"resistance_threshold_percent":50},"analyzed_at":"2026-01-30T19:15:30.390274","run_id":"ca125_1769818530"}},"wiwfm":{"status":"awaiting_ngs","message":"Personalized drug efficacy predictions require tumor NGS data (somatic mutations, HRD, TMB, MSI)","ngs_fast_track":{"ctDNA":"Guardant360 - somatic BRCA/HRR, TMB, MSI (7-10 days)","tissue_HRD":"MyChoice - HRD score for PARP maintenance planning (7-14 days)","IHC":"WT1/PAX8/p53 - confirm high-grade serous histology (1-3 days)"},"confidence":null,"note":"Once NGS available, WIWFM will provide Evo2-powered S/P/E drug ranking with 70-85% confidence"},"io_selection":{"eligible":true,"eligibility_signals":["PDL1_POSITIVE_CPS"],"eligibility_quality":"inferred","needs_confirmatory_biomarkers":["tmb","msi_status","mmr_status"],"evidence_gap":"Eligibility inferred from supportive signals (PD-L1 and/or hypermutator). Confirm with measured TMB/MSI/MMR when feasible.","selected_safest":{"selected":"avelumab","brand_name":"Bavencio","target":"PD-L1","irae_risk_raw":0.13,"irae_risk_adjusted":0.13,"risk_factors":[],"monitoring_priority":["infusion_reaction","pneumonitis"],"reason":"Lowest irAE risk (13%) among options","alternatives":[{"drug":"atezolizumab","brand_name":"Tecentriq","target":"PD-L1","moa_specific":"pdl1_inhibitor","irae_grade3plus_rate":0.14,"organ_specific_risks":{"pneumonitis":0.02,"hepatitis":0.02,"colitis":0.01,"thyroiditis":0.06,"dermatitis":0.03},"monitoring_priority":["pneumonitis","hepatitis"],"notes":"PD-L1 may have modestly lower irAE profile","adjusted_risk":0.14,"risk_factors":[]},{"drug":"durvalumab","brand_name":"Imfinzi","target":"PD-L1","moa_specific":"pdl1_inhibitor","irae_grade3plus_rate":0.15,"organ_specific_risks":{"pneumonitis":0.03,"hepatitis":0.02,"thyroiditis":0.07,"dermatitis":0.02},"monitoring_priority":["pneumonitis"],"notes":"Approved for lung cancer maintenance after chemoradiation","adjusted_risk":0.15,"risk_factors":[]},{"drug":"nivolumab","brand_name":"Opdivo","target":"PD-1","moa_specific":"pd1_inhibitor","irae_grade3plus_rate":0.16,"organ_specific_risks":{"pneumonitis":0.03,"colitis":0.02,"hepatitis":0.03,"thyroiditis":0.08,"hypophysitis":0.01,"myocarditis":0.01,"nephritis":0.02},"monitoring_priority":["pneumonitis","hepatitis","myocarditis"],"notes":"Similar to pembrolizumab, slightly different trial populations","adjusted_risk":0.16,"risk_factors":[]},{"drug":"pembrolizumab","brand_name":"Keytruda","target":"PD-1","moa_specific":"pd1_inhibitor","irae_grade3plus_rate":0.17,"organ_specific_risks":{"pneumonitis":0.04,"colitis":0.02,"hepatitis":0.02,"thyroiditis":0.1,"hypophysitis":0.01,"myocarditis":0.01,"nephritis":0.01},"monitoring_priority":["pneumonitis","myocarditis","thyroid"],"notes":"FDA approved for TMB-H (≥10 mut/Mb) solid tumors","adjusted_risk":0.17,"risk_factors":[]},{"drug":"ipilimumab","brand_name":"Yervoy","target":"CTLA-4","moa_specific":"ctla4_inhibitor","irae_grade3plus_rate":0.35,"organ_specific_risks":{"colitis":0.15,"hepatitis":0.05,"hypophysitis":0.05,"dermatitis":0.1,"thyroiditis":0.05,"myocarditis":0.02},"monitoring_priority":["colitis","hypophysitis","myocarditis"],"notes":"HIGHER irAE risk than PD-1. Reserve for specific indications or combinations.","adjusted_risk":0.35,"risk_factors":[]},{"drug":"nivolumab+ipilimumab","brand_name":"Nivo + Ipi","target":"PD-1 + CTLA-4","moa_specific":"combination_io","irae_grade3plus_rate":0.55,"organ_specific_risks":{"colitis":0.2,"hepatitis":0.15,"thyroiditis":0.15,"pneumonitis":0.08,"hypophysitis":0.08,"myocarditis":0.03,"nephritis":0.05},"monitoring_priority":["colitis","hepatitis","myocarditis","hypophysitis"],"notes":"HIGHEST irAE risk. Reserve for melanoma or when mono fails.","adjusted_risk":0.55,"risk_factors":[]}],"avoid":[{"drug":"ipilimumab","brand_name":"Yervoy","target":"CTLA-4","moa_specific":"ctla4_inhibitor","irae_grade3plus_rate":0.35,"organ_specific_risks":{"colitis":0.15,"hepatitis":0.05,"hypophysitis":0.05,"dermatitis":0.1,"thyroiditis":0.05,"myocarditis":0.02},"monitoring_priority":["colitis","hypophysitis","myocarditis"],"notes":"HIGHER irAE risk than PD-1. Reserve for specific indications or combinations.","adjusted_risk":0.35,"risk_factors":[]},{"drug":"nivolumab+ipilimumab","brand_name":"Nivo + Ipi","target":"PD-1 + CTLA-4","moa_specific":"combination_io","irae_grade3plus_rate":0.55,"organ_specific_risks":{"colitis":0.2,"hepatitis":0.15,"thyroiditis":0.15,"pneumonitis":0.08,"hypophysitis":0.08,"myocarditis":0.03,"nephritis":0.05},"monitoring_priority":["colitis","hepatitis","myocarditis","hypophysitis"],"notes":"HIGHEST irAE risk. Reserve for melanoma or when mono fails.","adjusted_risk":0.55,"risk_factors":[]}]},"candidates":[{"drug":"avelumab","brand_name":"Bavencio","target":"PD-L1","moa_specific":"pdl1_inhibitor","irae_grade3plus_rate":0.13,"organ_specific_risks":{"pneumonitis":0.02,"hepatitis":0.02,"colitis":0.01,"thyroiditis":0.05},"monitoring_priority":["infusion_reaction","pneumonitis"],"notes":"Higher infusion reaction rate than other PD-L1s"},{"drug":"atezolizumab","brand_name":"Tecentriq","target":"PD-L1","moa_specific":"pdl1_inhibitor","irae_grade3plus_rate":0.14,"organ_specific_risks":{"pneumonitis":0.02,"hepatitis":0.02,"colitis":0.01,"thyroiditis":0.06,"dermatitis":0.03},"monitoring_priority":["pneumonitis","hepatitis"],"notes":"PD-L1 may have modestly lower irAE profile"},{"drug":"durvalumab","brand_name":"Imfinzi","target":"PD-L1","moa_specific":"pdl1_inhibitor","irae_grade3plus_rate":0.15,"organ_specific_risks":{"pneumonitis":0.03,"hepatitis":0.02,"thyroiditis":0.07,"dermatitis":0.02},"monitoring_priority":["pneumonitis"],"notes":"Approved for lung cancer maintenance after chemoradiation"},{"drug":"nivolumab","brand_name":"Opdivo","target":"PD-1","moa_specific":"pd1_inhibitor","irae_grade3plus_rate":0.16,"organ_specific_risks":{"pneumonitis":0.03,"colitis":0.02,"hepatitis":0.03,"thyroiditis":0.08,"hypophysitis":0.01,"myocarditis":0.01,"nephritis":0.02},"monitoring_priority":["pneumonitis","hepatitis","myocarditis"],"notes":"Similar to pembrolizumab, slightly different trial populations"},{"drug":"pembrolizumab","brand_name":"Keytruda","target":"PD-1","moa_specific":"pd1_inhibitor","irae_grade3plus_rate":0.17,"organ_specific_risks":{"pneumonitis":0.04,"colitis":0.02,"hepatitis":0.02,"thyroiditis":0.1,"hypophysitis":0.01,"myocarditis":0.01,"nephritis":0.01},"monitoring_priority":["pneumonitis","myocarditis","thyroid"],"notes":"FDA approved for TMB-H (≥10 mut/Mb) solid tumors"},{"drug":"ipilimumab","brand_name":"Yervoy","target":"CTLA-4","moa_specific":"ctla4_inhibitor","irae_grade3plus_rate":0.35,"organ_specific_risks":{"colitis":0.15,"hepatitis":0.05,"hypophysitis":0.05,"dermatitis":0.1,"thyroiditis":0.05,"myocarditis":0.02},"monitoring_priority":["colitis","hypophysitis","myocarditis"],"notes":"HIGHER irAE risk than PD-1. Reserve for specific indications or combinations."},{"drug":"nivolumab+ipilimumab","brand_name":"Nivo + Ipi","target":"PD-1 + CTLA-4","moa_specific":"combination_io","irae_grade3plus_rate":0.55,"organ_specific_risks":{"colitis":0.2,"hepatitis":0.15,"thyroiditis":0.15,"pneumonitis":0.08,"hypophysitis":0.08,"myocarditis":0.03,"nephritis":0.05},"monitoring_priority":["colitis","hepatitis","myocarditis","hypophysitis"],"notes":"HIGHEST irAE risk. Reserve for melanoma or when mono fails."}],"ruo_disclaimer":"Research Use Only (RUO). This is decision support, not medical advice.","provenance":{"service":"io_safest_selection_service","version":"v1"}},"food_validation":null,"supplement_recommendations":null,"resistance_playbook":null,"next_test_recommender":{"recommendations":[{"test_name":"HRD Score (MyChoice CDx or tissue-based NGS)","priority":1,"turnaround_days":10,"cost_estimate":"$4,000-$6,000 (typically covered by insurance for Stage III/IV ovarian)","impact_if_positive":"HRD ≥42 → PARP maintenance eligible (NCCN Category 1). Unlock mechanism map DDR chip.","impact_if_negative":"HRD <42 → PARP reduced benefit. Consider ATR/CHK1 combo or platinum-only.","rationale":"HRD score determines PARP inhibitor eligibility and confidence level.","urgency":"high","test_type":"tissue","ordering_info":"Order via Myriad Genetics (MyChoice CDx) or comprehensive tumor NGS."},{"test_name":"ctDNA Comprehensive Panel (Guardant360 CDx or FoundationOne Liquid CDx)","priority":2,"turnaround_days":7,"cost_estimate":"$5,000-$7,000 (typically covered by insurance)","impact_if_positive":"MSI-High/TMB≥20 → IO eligible. Somatic HRR → PARP confidence 90%.","impact_if_negative":"MSI-Stable/TMB<20 → IO lower priority. No somatic HRR → Standard care.","rationale":"MSI/TMB unlock immunotherapy. Somatic HRR mutations enable PARP strategies.","urgency":"high","test_type":"blood","ordering_info":"Order via Guardant Health or Foundation Medicine. 2-3 tubes blood (EDTA)."}],"top_priority":{"test_name":"HRD Score (MyChoice CDx or tissue-based NGS)","priority":1,"turnaround_days":10,"cost_estimate":"$4,000-$6,000 (typically covered by insurance for Stage III/IV ovarian)","impact_if_positive":"HRD ≥42 → PARP maintenance eligible (NCCN Category 1). Unlock mechanism map DDR chip.","impact_if_negative":"HRD <42 → PARP reduced benefit. Consider ATR/CHK1 combo or platinum-only.","rationale":"HRD score determines PARP inhibitor eligibility and confidence level.","urgency":"high","test_type":"tissue","ordering_info":"Order via Myriad Genetics (MyChoice CDx) or comprehensive tumor NGS."},"total_tests":2,"high_priority_count":2,"checklist_markdown":"## 📋 NGS Fast-Track Checklist\n\n### Priority 1: HRD Score\n- **Test**: HRD Score (MyChoice CDx or tissue-based NGS)\n- **Turnaround**: 10 days\n- **Cost**: $4,000-$6,000 (typically covered by insurance for Stage III/IV ovarian)\n- **Urgency**: HIGH\n\n**What This Unlocks**:\n- ✅ If Positive: HRD ≥42 → PARP maintenance eligible (NCCN Category 1). Unlock mechanism map DDR chip....\n- ⚠️ If Negative: HRD <42 → PARP reduced benefit. Consider ATR/CHK1 combo or platinum-only....\n\n**Why**: HRD score determines PARP inhibitor eligibility and confidence level....\n\n**Ordering**: Order via Myriad Genetics (MyChoice CDx) or comprehensive tumor NGS.\n\n---\n\n### Priority 2: ctDNA Comprehensive Panel\n- **Test**: ctDNA Comprehensive Panel (Guardant360 CDx or FoundationOne Liquid CDx)\n- **Turnaround**: 7 days\n- **Cost**: $5,000-$7,000 (typically covered by insurance)\n- **Urgency**: HIGH\n\n**What This Unlocks**:\n- ✅ If Positive: MSI-High/TMB≥20 → IO eligible. Somatic HRR → PARP confidence 90%....\n- ⚠️ If Negative: MSI-Stable/TMB<20 → IO lower priority. No somatic HRR → Standard care....\n\n**Why**: MSI/TMB unlock immunotherapy. Somatic HRR mutations enable PARP strategies....\n\n**Ordering**: Order via Guardant Health or Foundation Medicine. 2-3 tubes blood (EDTA).\n\n---\n","provenance":{"version":"v1.1","policy_source":"MANAGER_ANSWERS_TO_ZO_SAE_QUESTIONS.md (P1, C6) + Resistance Prophet","manager":"SR + Zo","date":"2025-01-28","note":"Includes Resistance Prophet Integration"}},"hint_tiles":{"hint_tiles":[{"category":"next_test","title":"📋 Recommended Next Test","message":"Consider ordering HRD Score","reasons":["HRD score determines PARP inhibitor eligibility and confidence level....","Turnaround: 10 days","Unlocks: HRD ≥42 → PARP maintenance eligible (NCCN Category 1). Unlock mechanism map DDR chip...."],"priority":1,"icon":"🧪","action_link":"/ngs-fast-track","provenance":"next_test_recommender.priority_1"},{"category":"trials_lever","title":"🎯 Mechanism-Matched Trials","message":"Consider mechanism-aligned trials (10 matched)","reasons":["Mechanism fit calculated from tumor genomics","10 trials align with detected pathway burden","Ranked by eligibility (70%) + mechanism fit (30%)"],"priority":2,"icon":"🎯","action_link":"/ayesha-trials","provenance":"mechanism_fit_ranker.post_ngs"}],"total_tiles":2,"categories":["next_test","trials_lever"],"by_category":{"next_test":{"category":"next_test","title":"📋 Recommended Next Test","message":"Consider ordering HRD Score","reasons":["HRD score determines PARP inhibitor eligibility and confidence level....","Turnaround: 10 days","Unlocks: HRD ≥42 → PARP maintenance eligible (NCCN Category 1). Unlock mechanism map DDR chip...."],"priority":1,"icon":"🧪","action_link":"/ngs-fast-track","provenance":"next_test_recommender.priority_1"},"trials_lever":{"category":"trials_lever","title":"🎯 Mechanism-Matched Trials","message":"Consider mechanism-aligned trials (10 matched)","reasons":["Mechanism fit calculated from tumor genomics","10 trials align with detected pathway burden","Ranked by eligibility (70%) + mechanism fit (30%)"],"priority":2,"icon":"🎯","action_link":"/ayesha-trials","provenance":"mechanism_fit_ranker.post_ngs"}},"summary_text":"## 🎯 Recommended Actions\n\n### 🧪 📋 Recommended Next Test\n**Consider ordering HRD Score**\n\n**Why:**\n- HRD score determines PARP inhibitor eligibility and confidence level....\n- Turnaround: 10 days\n- Unlocks: HRD ≥42 → PARP maintenance eligible (NCCN Category 1). Unlock mechanism map DDR chip....\n\n### 🎯 🎯 Mechanism-Matched Trials\n**Consider mechanism-aligned trials (10 matched)**\n\n**Why:**\n- Mechanism fit calculated from tumor genomics\n- 10 trials align with detected pathway burden\n- Ranked by eligibility (70%) + mechanism fit (30%)\n","provenance":{"version":"v1.0","policy_source":"MANAGER_ANSWERS_TO_ZO_SAE_QUESTIONS.md (P5, C8)","manager":"SR","date":"2025-01-13","max_tiles":4,"tone":"suggestive","note":"Priority: Test → Trials → Monitor → Avoid. Pre-NGS excludes 'avoid' tile."}},"mechanism_map":{"chips":[{"pathway":"DDR","burden":0.0,"color":"default","label":"Awaiting NGS","tooltip":"DNA damage repair pathway burden - requires tumor NGS to assess. High burden (≥70%) indicates PARP/ATR/CHK1 eligibility.","status":"awaiting_ngs"},{"pathway":"MAPK","burden":0.0,"color":"default","label":"Awaiting NGS","tooltip":"RAS/RAF/MEK pathway burden - requires tumor NGS. High burden (≥70%) indicates MEK/RAF inhibitor eligibility.","status":"awaiting_ngs"},{"pathway":"PI3K","burden":0.0,"color":"default","label":"Awaiting NGS","tooltip":"PI3K/AKT/mTOR pathway burden - requires tumor NGS. High burden (≥70%) indicates PI3K/mTOR inhibitor eligibility.","status":"awaiting_ngs"},{"pathway":"VEGF","burden":0.0,"color":"default","label":"Awaiting NGS","tooltip":"Angiogenesis pathway burden - requires tumor NGS. High burden (≥70%) supports bevacizumab addition.","status":"awaiting_ngs"},{"pathway":"IO","burden":0.0,"color":"default","label":"Awaiting NGS","tooltip":"Immune checkpoint pathway - requires MSI/TMB testing. MSI-High OR TMB ≥20 → Immunotherapy eligible.","status":"awaiting_ngs"},{"pathway":"Efflux","burden":0.0,"color":"default","label":"Awaiting NGS","tooltip":"Drug efflux resistance (ABCB1) - requires tumor NGS. High expression → Cross-resistance to taxanes/anthracyclines.","status":"awaiting_ngs"}],"status":"awaiting_ngs","message":"Mechanism map will be available once tumor NGS results are uploaded (7-10 days). Order HRD + ctDNA to unlock.","provenance":{"mode":"pre_ngs","policy":"All chips gray per Manager C9"}},"sae_features":{"dna_repair_capacity":0.3,"pathway_burden_ddr":0.5,"pathway_burden_mapk":0.2,"pathway_burden_pi3k":0.2,"pathway_burden_vegf":0.3,"pathway_burden_her2":0.0,"io_eligible":false,"cross_resistance_risk":0.0,"essentiality_hrr_genes":0.0,"exon_disruption_score":0.0,"hotspot_mutation":false,"hotspot_details":null,"mechanism_vector":[0.5,0.2,0.2,0.3,0.0,0.0,0.0],"resistance_signals":{"resistance_detected":false,"triggers":[],"reasons":[],"policy":"2-of-3 trigger rule (MANAGER_ANSWERS_TO_ZO_SAE_QUESTIONS.md C7)"},"provenance":{"data_sources":{"insights_bundle":"Functionality, Chromatin, Essentiality, Regulatory","pathway_scores":"P from efficacy router","tumor_context":"HRD=None, TMB=0.0, MSI=Unknown","treatment_history":"0 treatments","ca125_intelligence":"Included"},"insights_bundle_values":{"functionality":0.5,"chromatin":0.5,"essentiality":0.5,"regulatory":0.5},"manager_policy":"MANAGER_ANSWERS_TO_ZO_SAE_QUESTIONS.md (C1-C10)","thresholds":{"pathway_high":0.7,"pathway_moderate":0.4,"essentiality_contribution_weight":0.15,"exon_disruption_threshold":0.65,"mechanism_fit_alpha":0.7,"mechanism_fit_beta":0.3},"sae":"proxy"}},"resistance_alert":{"resistance_detected":false,"hr_restoration_suspected":false,"immediate_alert":false,"triggers_met":[],"trigger_count":0,"hrd_signal":{"triggered":false,"reason":"No baseline HRD available"},"dna_repair_signal":{"triggered":false,"reason":"No baseline DNA repair capacity available"},"ca125_signal":{"triggered":false,"reason":"CA-125 response adequate (on track)","details":{}},"recommended_actions":[],"recommended_trials":[],"timestamp":"2026-01-30T14:15:30.392053","provenance":{"detection_me100 75868  100 75408  100   460   469k   2932 --:--:-- --:--:-- --:--:--  474k
* Connection #0 to host 127.0.0.1 left intact
thod":"2-of-3 trigger rule + HR restoration pattern","manager_policy":"MANAGER_ANSWERS_TO_ZO_SAE_QUESTIONS.md (C7, R2)","thresholds":{"hrd_drop":15,"dna_repair_drop":0.2,"ca125_drop_cycle3":0.5,"hr_restoration_hrd_min":10,"hr_restoration_dna_repair_min":0.15},"triggers_evaluated":["hrd_drop","dna_repair_drop","ca125_inadequate"],"triggers_met":[],"trigger_count":0,"resistance_logic":"2-of-3 triggers OR HR restoration pattern"}},"resistance_prediction":null,"summary":{"components_included":["clinical_trials","soc_recommendation","ca125_monitoring","wiwfm","next_test_recommender","hint_tiles","mechanism_map"],"ngs_status":"available","confidence_level":"moderate-high (70-90%)","reasoning":"Confidence is high for guideline-based recommendations (trials, SOC, CA-125). Confidence is moderate for personalized predictions (WIWFM requires NGS)."},"provenance":{"orchestrator":"complete_care_v2_modular","for_patient":"AK (Stage IVB ovarian cancer)","endpoints_called":["clinical_trials","soc_recommendation","ca125_monitoring","wiwfm","next_test_recommender","hint_tiles","mechanism_map"],"ngs_status":"available","generated_at":"2026-01-30T19:15:30.392327","run_id":"complete_care_v2_1769818530","note":"This is NOT a demo. Real clinical decision support for Ayesha's life.","sae_phase1_enabled":true,"sae_services":["next_test_recommender","hint_tiles","mechanism_map"],"resistance_prophet_enabled":false,"resistance_prophet_phase":"phase1_retrospective_no_ca125","manager_policy_sae":"MANAGER_ANSWERS_TO_ZO_SAE_QUESTIONS.md (Jan 13, 2025)","manager_policy_prophet":"MANAGER_ANSWERS_TO_RESISTANCE_PROPHET_QUESTIONS.md (Jan 14, 2025)","architecture":"modular_service_based"}}